SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015298
Filing Date
2021-11-09
Accepted
2021-11-09 16:15:43
Documents
64
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20210930x10q.htm   iXBRL 10-Q 2161962
2 EX-10.1 nbrv-20210930xex10d1.htm EX-10.1 176651
3 EX-10.2 nbrv-20210930xex10d2.htm EX-10.2 166689
4 EX-31.1 nbrv-20210930xex31d1.htm EX-31.1 10557
5 EX-31.2 nbrv-20210930xex31d2.htm EX-31.2 11272
6 EX-32.1 nbrv-20210930xex32d1.htm EX-32.1 5758
7 EX-32.2 nbrv-20210930xex32d2.htm EX-32.2 6291
  Complete submission text file 0001558370-21-015298.txt   7688434

Data Files

Seq Description Document Type Size
8 EX-101.SCH nbrv-20210930.xsd EX-101.SCH 56645
9 EX-101.CAL nbrv-20210930_cal.xml EX-101.CAL 45076
10 EX-101.DEF nbrv-20210930_def.xml EX-101.DEF 216654
11 EX-101.LAB nbrv-20210930_lab.xml EX-101.LAB 478160
12 EX-101.PRE nbrv-20210930_pre.xml EX-101.PRE 336059
13 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20210930x10q_htm.xml XML 1035689
Mailing Address 414 COMMERCE DRIVE STE 120 FORT WASHINGTON PA 19034
Business Address 25-28 NORTH WALL QUAY DUBLIN L2 D01 H104 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 211392374
SIC: 2834 Pharmaceutical Preparations